COSS Registry

Osteosarcoma

Register ohne Vorgaben zur Therapie

The COSS study center includes patients who are newly treated for an osteosarcoma from 1 July 2011 in the COSS register. For patients registered in the COSS registry, the infrastructure of the COSS group remains available for consultation and reference assessment.

Naturally, the COSS registry does not contain any guidelines for therapy. However, after consultation with its partners from the European Osteosarcoma Intergroup, the Scandinavian Sarcoma Group and the Childrens' Oncology Group, the COSS study management recommends the following procedure for patients outside of studies:
The standard of care recommended by the EURAMOS-1 Trial Management Group for newly diagnosed patients with resectable osteosarcoma is MAP (methotrexate, doxorubicin, cisplatin) without any adjustment of postoperative treatment.
The COSS study center and the associated COSS reference institutions have been dealing with quality assurance and other special aspects of diagnostics and therapy for many years. Their work serves the goal of ensuring a consistently high quality of care and thus benefits the individual patient directly.
In addition to the COSS center itself, these are essentially reference pathology (to confirm the diagnosis), reference radiology (to ensure the spread of the disease), reference surgery and reference radiation therapy (to plan local therapy).
In principle, the treating physicians of all affected patients are offered consultation by the specially trained COSS experts. The members of the COSS study group offer their advice, particularly in the case of difficult clinical decisions or emergencies.

Primary diagnosis of osteosarcoma
Age up to 40 years
Consent to the storage and evaluation of personal data